This case highlights the diagnostic and management challenges of refractory multisystem sarcoidosis progressing over a two-year period despite advanced biologic therapy.
Clinical context
As robotic-assisted bronchoscopy (RAB) becomes the standard for peripheral pulmonary nodule (PPN) biopsy, the role of Rapid On-Site Evaluation (ROSE) remains debated. While ROSE is standard in EBUS-TBNA, its utility in the peripheral lung—where samples are often smaller and subject to different diagnostic yields—is critical for optimizing procedural efficiency and reducing the need for repeat interventions.
Strengths and weaknesses
Takeaway
ROSE in peripheral robotic cases is not just about confirming malignancy; it is about confirming tissue adequacy to prevent 'dry' passes. While it adds time to the procedure, it significantly reduces the risk of non-diagnostic results. Fellows should prioritize clear communication with the cytopathology team regarding the specific challenges of peripheral sampling (e.g., crush artifact, small volume) to maximize the utility of the on-site assessment.
Abstract
Keep reading
N opens the next oneClinicians should note that the presence of targetable mutations in non-small cell lung cancer with malignant pleural disease is not associated with improved survival, based on the findings from this study.
Shape-sensing robotic-assisted bronchoscopy achieved a strict diagnostic yield of 70.2% with a low pneumothorax rate of 3.3%, demonstrating that earlier tissue diagnosis of very small pulmonary nodules is feasible and safe for clinical practice.
CT-guided fiducial placement remains a relevant technique for pre-procedural localization of peripheral lung lesions.
This study introduces ultrasound-guided trans-cannula cryobiopsy of supraclavicular lymph nodes as a novel superficial lymph node approach for tissue acquisition in 10 consecutive patients, though specific numeric success or safety results were not provided in the abstract.
Active infection is not an absolute contraindication to endobronchial valve placement, but positive pressure ventilation significantly increases clinical failure odds with an aOR of 3.00 at P < 0.001.